Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
Blood
.
2016 Sep 8;128(10):1316-7.
doi: 10.1182/blood-2016-07-724948.
Authors
Naval Daver
1
,
Marina Konopleva
1
Affiliation
1
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
PMID:
27609539
DOI:
10.1182/blood-2016-07-724948
No abstract available
Publication types
Comment
MeSH terms
Apoptosis
Humans
Proto-Oncogene Proteins c-bcl-2*
bcl-X Protein*
Substances
Proto-Oncogene Proteins c-bcl-2
bcl-X Protein
Grants and funding
P30 CA016672/CA/NCI NIH HHS/United States